MHC class II and CD80 tumor cell–based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain

Author: Ilkovitch Dan   Ostrand-Rosenberg Suzanne  

Publisher: Springer Publishing Company

ISSN: 0340-7004

Source: Cancer Immunology, Immunotherapy, Vol.53, Iss.6, 2004-06, pp. : 525-532

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content